[{"id":"902fa0f5-f66c-4ff7-8f26-b928d9d04236","acronym":"MK-2118-001","url":"https://clinicaltrials.gov/study/NCT03249792","created_at":"2021-01-29T07:15:19.617Z","updated_at":"2024-07-02T16:35:52.271Z","phase":"Phase 1","brief_title":"Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)","source_id_and_acronym":"NCT03249792 - MK-2118-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MK-2118"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 02/22/2023","primary_completion_date":" 02/22/2023","study_txt":" Completion: 02/22/2023","study_completion_date":" 02/22/2023","last_update_posted":"2023-03-27"}]